11.22
+3.03%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CARsgen Therapeutics Holdings
Its shares trade on HKEX under the ticker 2171.HK. It has been listed since 18 June 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥146.3m and a net loss of CN¥113.9m. At that date it held total assets of CN¥1.50bn and shareholders' equity of CN¥912.2m.
CARsgen Therapeutics Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in discovering, researching, and developing cell therapies. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jun 2021
- Employees
- 525
- Website
- carsgen.com ↗
Leadership
Pay as last reported
- Mr. Zonghai LiExecutive Chairman of the Board, Chief Executive Officer, Chief Scientific Officer, since 2014HK$1.6m
- Mr. Richard DalyPresident of CARsgen Therapeutics Corporation
- Mr. Huamao WangChief Operating Officer, Executive Director, since 2018HK$2.2m
- Ms. Lan XieSenior Vice President - Finance
- Dr. Yong FanSenior Vice President - Global Regulatory Affairs
- Mr. Leigh HsuSenior Vice President - Business Development
- Dr. Hong MaSenior Vice President - Clinical Development
- Dr. Jie JiaVice President - Strategic Alliances and Operations
- Dr. Wei WangVice President
- Dr. Hua JiangExecutive Director, since 2022
- Dr. Raffaele BaffaChief Medical Officer
- Mr. Wing Yat LuiCompany Secretary
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CARsgen Therapeutics' CT053 targets BCMA for hematological malignancies treatment in China.
- The company operates in both China and the United States with 525 employees.
- CT053 is the sole core product candidate for solid tumors and hematological malignancies.
Weaknesses
- The company has only one core product candidate, CT053, for all treatments.
- Limited business presence outside China and the United States markets.
- No additional product candidates beyond CT053 for hematological malignancies.
Opportunities
- Expanding CT053 applications for solid tumors in the United States market.
- Growing demand for CAR-T therapies in China's healthcare sector.
- Potential partnerships for biopharmaceutical development in the United States.
Threats
- Competition from other biopharmaceutical companies in the United States market.
- Regulatory challenges for CAR-T therapies in China's healthcare system.
- Dependence on CT053 for all therapeutic applications in the market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.